514 related articles for article (PubMed ID: 10102971)
1. Is maintenance therapy always necessary for patients with ulcerative colitis in remission?
Ardizzone S; Petrillo M; Imbesi V; Cerutti R; Bollani S; Bianchi Porro G
Aliment Pharmacol Ther; 1999 Mar; 13(3):373-9. PubMed ID: 10102971
[TBL] [Abstract][Full Text] [Related]
2. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
3. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
Clemett D; Markham A
Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
[TBL] [Abstract][Full Text] [Related]
4. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.
Schroeder KW
Scand J Gastroenterol Suppl; 2002; (236):42-7. PubMed ID: 12408503
[TBL] [Abstract][Full Text] [Related]
5. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Kamm MA; Sandborn WJ; Gassull M; Schreiber S; Jackowski L; Butler T; Lyne A; Stephenson D; Palmen M; Joseph RE
Gastroenterology; 2007 Jan; 132(1):66-75; quiz 432-3. PubMed ID: 17241860
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol.
Prantera C; Kohn A; Campieri M; Caprilli R; Cottone M; Pallone F; Savarino V; Sturniolo GC; Vecchi M; Ardia A; Bellinvia S
Aliment Pharmacol Ther; 2009 Nov; 30(9):908-18. PubMed ID: 19678813
[TBL] [Abstract][Full Text] [Related]
7. Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?
Nakshabendi IM; Duncan A; Russell RI
Postgrad Med J; 1992 Mar; 68(797):189-91. PubMed ID: 1350343
[TBL] [Abstract][Full Text] [Related]
8. Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial.
Paoluzi P; D'Albasio G; Pera A; Bianchi Porro G; Paoluzi OA; Pica R; Cottone M; Miglioli M; Prantera C; Sturniolo G; Ardizzone S
Dig Liver Dis; 2002 Nov; 34(11):787-93. PubMed ID: 12546514
[TBL] [Abstract][Full Text] [Related]
9. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group.
Ann Intern Med; 1996 Jan; 124(2):204-11. PubMed ID: 8533995
[TBL] [Abstract][Full Text] [Related]
10. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study.
Vecchi M; Meucci G; Gionchetti P; Beltrami M; Di Maurizio P; Beretta L; Ganio E; Usai P; Campieri M; Fornaciari G; de Franchis R
Aliment Pharmacol Ther; 2001 Feb; 15(2):251-6. PubMed ID: 11148445
[TBL] [Abstract][Full Text] [Related]
11. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.
Timmer A; McDonald JW; Tsoulis DJ; Macdonald JK
Cochrane Database Syst Rev; 2012 Sep; (9):CD000478. PubMed ID: 22972046
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study.
Paoluzi OA; Iacopini F; Pica R; Crispino P; Marcheggiano A; Consolazio A; Rivera M; Paoluzi P
Aliment Pharmacol Ther; 2005 May; 21(9):1111-9. PubMed ID: 15854173
[TBL] [Abstract][Full Text] [Related]
13. Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study.
Marteau P; Crand J; Foucault M; Rambaud JC
Gut; 1998 Feb; 42(2):195-9. PubMed ID: 9536943
[TBL] [Abstract][Full Text] [Related]
14. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.
Kamm MA; Lichtenstein GR; Sandborn WJ; Schreiber S; Lees K; Barrett K; Joseph R
Gut; 2008 Jul; 57(7):893-902. PubMed ID: 18272546
[TBL] [Abstract][Full Text] [Related]
15. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.
Prakash A; Markham A
Drugs; 1999 Mar; 57(3):383-408. PubMed ID: 10193690
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.
Nguyen NH; Fumery M; Dulai PS; Prokop LJ; Sandborn WJ; Murad MH; Singh S
Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):742-753. PubMed ID: 30122356
[TBL] [Abstract][Full Text] [Related]
17. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.
Timmer A; Patton PH; Chande N; McDonald JW; MacDonald JK
Cochrane Database Syst Rev; 2016 May; 2016(5):CD000478. PubMed ID: 27192092
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis.
Pica R; Cassieri C; Cocco A; Zippi M; Marcheggiano A; De Nitto D; Avallone EV; Crispino P; Occhigrossi G; Paoluzi P
Dig Liver Dis; 2015 Nov; 47(11):933-7. PubMed ID: 26391602
[TBL] [Abstract][Full Text] [Related]
19. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
[TBL] [Abstract][Full Text] [Related]
20. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group.
Green JR; Gibson JA; Kerr GD; Swarbrick ET; Lobo AJ; Holdsworth CD; Crowe JP; Schofield KJ; Taylor MD
Aliment Pharmacol Ther; 1998 Dec; 12(12):1207-16. PubMed ID: 9882028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
